Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
ID: 356552Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $400K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356552

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-022.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)," aimed at establishing Recruitment Sites (RS) for enrolling individuals with Type 1 diabetes (T1D) who are at risk of nephropathy. This initiative seeks applications for a longitudinal cohort study that will involve obtaining kidney biopsies and conducting comprehensive clinical phenotyping, with a focus on ethical practices and inclusivity to enhance understanding of T1D nephropathy and identify potential therapeutic targets. The funding opportunity has a budget of approximately $1.3 million, with individual awards of up to $400,000 in direct costs annually, and key deadlines include a letter of intent due on November 11, 2024, with applications closing on December 10, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DK-25-022-Full-Announcement.html
    RFA-DK-25-022.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a funding opportunity aimed at establishing Recruitment Sites (RS) focused on enrolling individuals with Type 1 diabetes (T1D) at risk of nephropathy. The initiative seeks applications for a longitudinal cohort study to obtain kidney biopsies and conduct comprehensive clinical phenotyping linked to social determinants of health. Emphasizing ethical practices, participant safety, and inclusivity, the program aims to enhance understanding of T1D nephropathy by identifying molecular pathways and potential therapeutic targets while leveraging the Kidney Precision Medicine Project (KPMP). No clinical trials are permitted under this funding opportunity, with a budget of approximately $1.3 million for 2 to 3 awards, each expected to include up to $400,000 in direct costs annually. Applicants should demonstrate multidisciplinary expertise and capabilities to recruit diverse cohorts, ensuring compliance with established KPMP protocols and governance. The application deadlines begin with a letter of intent due on November 11, 2024. This opportunity reflects the commitment to improve outcomes for individuals with T1D and tackle the significant burden associated with diabetic kidney disease.
    Similar Opportunities
    Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for collaborative research projects focused on type 1 diabetes, specifically utilizing biosamples and data from established clinical studies. The objective is to advance the understanding of the disease's etiology and pathogenesis, with funding available for studies that aim to explore disease mechanisms, delay onset, and improve prevention strategies. A total of $5.5 million is committed for up to four awards in Fiscal Years 2026 and 2027, with application deadlines beginning on May 26, 2025, and a final submission date of March 9, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated, high-risk multi-center clinical trials through the Notice of Funding Opportunity (NOFO) PA-25-147. This cooperative agreement (U01) aims to support innovative studies that address critical health issues related to diabetes, digestive diseases, and kidney conditions, requiring proposals to be hypothesis-driven and operationally classified as high-risk. The program emphasizes the importance of diverse perspectives in research and mandates that planning activities be completed prior to application submission. Interested applicants should note that the application period opens on January 3, 2025, with a submission deadline of November 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk, multi-center observational studies related to diabetes, digestive, kidney, and associated diseases. This funding opportunity emphasizes hypothesis-driven research that engages diverse populations, particularly underserved communities, and requires a comprehensive study design, community engagement, and a detailed budget. The initiative is crucial for advancing health equity and enhancing participant diversity in clinical research. Interested applicants should note that the submission period opens on January 3, 2025, with a closing date of November 5, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)." This initiative aims to support high-risk, investigator-initiated, multi-center clinical studies by facilitating early peer review and the development of essential operational documents necessary for conducting the proposed studies. The program emphasizes the importance of addressing diseases affecting underrepresented populations and requires applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) in their submissions. The maximum award amount is $225,000 per year for up to two years, with applications opening on May 9, 2025, and a submission deadline of June 10, 2027. Interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Impact, Interdisciplinary Science in NIDDK Research Areas" (PAR-25-277) aimed at supporting innovative research that addresses critical knowledge gaps in diabetes, digestive, and kidney diseases. This grant program encourages interdisciplinary approaches to foster discovery-based science and develop transformative technologies that can significantly impact the broader scientific community. Eligible applicants include a wide range of organizations, such as higher education institutions and nonprofits, with proposals accepted for projects lasting up to five years. Interested parties should ensure compliance with application guidelines and submit their proposals by the deadline of October 15, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-277.html.
    NIDDK Centers for Diabetes Translation Research (P30 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Centers for Diabetes Translation Research (CDTR) under the funding opportunity RFA-DK-26-001, aimed at advancing diabetes translational research from clinical settings to community practice. This initiative seeks to foster innovative research that addresses health equity and reduces diabetes-related disparities through multidisciplinary collaborations and core services that enhance productivity and synergy among funded investigators. Eligible applicants include a wide range of institutions, such as higher education institutions, nonprofits, and government entities, with annual budgets capped at $400,000, potentially increasing to $500,000 for specific cores. Applications are due by May 12, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the New Investigator Gateway Awards for Collaborative Type 1 Diabetes (T1D) Research under the R03 Small Grant Program. This funding initiative aims to support innovative research and foster talent among new investigators in T1D, allowing awardees to engage in ongoing collaborations within established research networks to enhance their understanding of significant research questions. The program emphasizes critical areas such as the human islet environment, autoimmune diabetes models, and non-invasive biomarker development, ultimately fostering long-term collaborative relationships that will advance the field. Interested applicants can apply for grants up to $100,000 per year, with applications due by 5:00 PM local time on March 6, 2026. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-009.html.